Kanada - enska - Health Canada

sandoz canada incorporated - granisetron (granisetron hydrochloride) - solution - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Kanada - enska - Health Canada

natco pharma (canada) inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 1.12 mg/ml (equivalent: granisetron, qty 1 mg/ml) - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium hydroxide; sodium chloride; hydrochloric acid - adults:,kytril (tablets and injection) is indicated for use in adults for:,the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy. kytril (injection) is also indicated for use in the treatment of nausea and vomiting induced by cytotoxic chemotherapy; and prevention and treatment of post-operative nausea and vomiting.,paediatric:,kytril injection is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Kanada - enska - Health Canada

jamp pharma corporation - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Írland - enska - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - granisetron hydrochloride - concentrate for soln for inf - 1 mg/ml - serotonin (5ht3) antagonists

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 2.24 mg (equivalent: granisetron, qty 2 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium starch glycollate; hypromellose; titanium dioxide; polysorbate 80; macrogol 400 - adults: kytril (tablets and injection) is indicated for use in adults for: the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy.

Kanada - enska - Health Canada

apotex inc - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Kanada - enska - Health Canada

hoffmann-la roche limited - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

rex medical ltd - granisetron hydrochloride 1.12mg equivalent to 1.0 mg granisetron base - film coated tablet - 1 mg - active: granisetron hydrochloride 1.12mg equivalent to 1.0 mg granisetron base excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white 04f58804 purified water   sodium starch glycolate - granisetron is indicated for the prevention of acute and delayed nausea and vomiting associated with cytostatic therapy

Bandaríkin - enska - NLM (National Library of Medicine)

wockhardt usa llc. - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron 0.1 mg in 1 ml - granisetron hydrochloride injection is a serotonin-3 (5-ht3 ) receptor antagonist indicated for: - the prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (eg. anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components. pregnancy  category  b reproduction studies have been performed in pregnant rats at intravenous doses up to 9 mg/kg/day (54 mg/m2 /day, 146 times the recommended human dose based on body surface area) and pregnant rabbits at intravenous doses up to 3 mg/kg/day (35.4 mg/m2 /day, 96 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predi